The U.S. Federal Trade Commission (FTC) challenge to Illumina’s planned $1.2 billion acquisition of Pacific Biosciences (PacBio) on anti-competitiveness grounds is unlikely to weaken its standing as the dominant company in next-generation sequencing, three analysts tell GEN Edge.
Aptadir engineers RNA therapies that inhibit DNMT-1 to prevent methylation in genes associated with myelodysplastic syndrome and other disorders.
The strategic collaboration will provide Recipharm with access to Exela’s manufacturing facility located in Lenoir, NC.
Industry, academic institutions, suppliers, and regulatory agencies working together can yield state-of-the-art downstream processes.
KBI Biopharma says they’re selecting the best technologies to fill gaps in their processes with grassroots help from their scientific staff.
Researchers recommend verifying success of column-based purification to confirm the presence and availability of the tag on target protein.
Quell’s proprietary platform has been developed to generate engineered CAR-Treg cell therapies that can be directed to specific tissues.
Poseida Therapeutics’ lead allogeneic chimeric antigen receptor T-cell candidate it is co-developing with Roche will advance to Phase Ib.
Aptadir engineers RNA therapies that inhibit DNMT-1 to prevent methylation in genes associated with myelodysplastic syndrome and other disorders.
The first wiring diagram of every neuron in an adult brain, and the 50 million connections between them, has been produced for Drosophila.
Poseida Therapeutics’ lead allogeneic chimeric antigen receptor T-cell candidate it is co-developing with Roche will advance to Phase Ib.
